# Ambledown 2024 benefit updates

# Overall Aggregate Increase 9,5%

### Current Annual Overall Limit

# R 198,660

To be increased on 1 April 2024 as per Regulatory Requirements

### Additional procedures have been included for LPE

- Tonsillectomies,
- Myringotomies, and
- Adenoidectomies.



One Penalty Co-payment increases from R13 000 to





### Upgrade to Extended Cancer Interventions

Addition of new cancer drug treatments including biological, immunotherapies, and targeted therapies (including small molecule drugs) to complete our coverage and make it one of the most comprehensive in the Gap Cover market.



# All Casualty Ward Benefits to increase from R10,000 to

R 11,000

This is not a medical scheme and the cover is not the same as that of a medical scheme. This policy is not a substitute for medical scheme membership.





Guardrisk Insurance Company Limited, a licensed non-life Insurer and an authorised financial services provider (No.75)

## Extended Cancer Intervention drug list



### Available therapies

- Biological cancer drugs
- Immunotherapy
- Hormone Therapy
- Targeted Therapy (including Small Molecule Drugs)
- Photodynamic Therapy
- Stem Cell Transplant



### **Biological Cancer Drugs**

#### NEW

- Kadcyla (ado-trastuzumab emtansine)
- Enhertu
- Venetoclax
- Obinutuzumab
- Rituximab
- Herceptin

#### EXISTING

- Mylotarg
- Nexavar
- Gleevec
- Sprycel
- Faslodex
- Velcade
- Tarceva

• Alimta

•

- Zevalin •
- Avastin
- Erbitux
- Sunitinib
- Sutent
- Fludara

- Mabthera
- Votrient
  - Gemzar
  - Cisplatin
  - Everolimus

This is not a medical scheme and the cover is not the same as that of a medical scheme. This policy is not a substitute for medical scheme membership.



